Literatura científica selecionada sobre o tema "Maladie de Castleman – Thérapeutique"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Índice
Consulte a lista de atuais artigos, livros, teses, anais de congressos e outras fontes científicas relevantes para o tema "Maladie de Castleman – Thérapeutique".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Artigos de revistas sobre o assunto "Maladie de Castleman – Thérapeutique"
Valade, S., E. Canet e E. Mariotte. "Syndrome d’activation macrophagique d’origine infectieuse : le point de vue du réanimateur". Médecine Intensive Réanimation 27, n.º 3 (maio de 2018): 239–48. http://dx.doi.org/10.3166/rea-2018-0048.
Texto completo da fonteGalicier, L., e N. Schleinitz. "Approche thérapeutique des maladies de Castleman : l’émergence des thérapies ciblées". La Revue de Médecine Interne 43, n.º 10 (dezembro de 2022): 10S26–10S33. http://dx.doi.org/10.1016/s0248-8663(23)00022-x.
Texto completo da fonteMaloisel, F., E. Andrès, F. Campos, C. Opréa, M. Deslandres, R. Randriamahazaka, J. E. Kurtz, A. Koumarianou e P. Dufour. "Y a-t-il une place pour l'interféron-α dans la stratégie thérapeutique de la maladie de Castleman multicentrique?" La Revue de Médecine Interne 21, n.º 5 (maio de 2000): 435–38. http://dx.doi.org/10.1016/s0248-8663(00)88954-7.
Texto completo da fonteLarroche, C., P. Cacoub e P. Godeau. "La maladie de Castleman". La Revue de Médecine Interne 17, n.º 12 (dezembro de 1996): 1003–13. http://dx.doi.org/10.1016/s0248-8663(97)80844-2.
Texto completo da fonteGuandalino, M., J. Largeron, J. L. Kemeny, J. P. Boiteux e L. Guy. "Maladie de Castleman rétropéritonéale". Progrès en Urologie 23, n.º 13 (novembro de 2013): 1066. http://dx.doi.org/10.1016/j.purol.2013.08.110.
Texto completo da fonteGhribi, M., A. Derbel, F. Mkaouar, C. Damak, F. Frikha, M. Sameh e Z. Bahloul. "Maladie de Castleman et biothérapie". La Revue de Médecine Interne 41 (dezembro de 2020): A124. http://dx.doi.org/10.1016/j.revmed.2020.10.208.
Texto completo da fontePiguet, C., C. Dubouillé, B. Petit, B. Longis, E. Paseaud e L. De Lumley. "Maladie de Castleman chez l'enfant". Archives de Pédiatrie 11, n.º 10 (outubro de 2004): 1252–54. http://dx.doi.org/10.1016/j.arcped.2004.06.035.
Texto completo da fonteOksenhendler, E. "Éditorial - Maladie(s) de Castleman". La Revue de Médecine Interne 43, n.º 10 (dezembro de 2022): 10S1–10S3. http://dx.doi.org/10.1016/s0248-8663(23)00018-8.
Texto completo da fonteTbessi, R., M. S. Hamdi, I. Kechaou, A. Hariz, E. Cherif, S. Azzabi, K. Chakib, I. Boukhris e L. Ben Hassine. "Maladie de Castleman : un challenge diagnostique". La Revue de Médecine Interne 43 (junho de 2022): A182. http://dx.doi.org/10.1016/j.revmed.2022.03.099.
Texto completo da fonteDégot, T., A. C. Métivier, S. Casnedi, M. P. Chenard e R. Kessler. "Maladie de Castleman à expression thoracique". Revue de Pneumologie Clinique 65, n.º 2 (abril de 2009): 101–7. http://dx.doi.org/10.1016/j.pneumo.2008.12.004.
Texto completo da fonteTeses / dissertações sobre o assunto "Maladie de Castleman – Thérapeutique"
Gothland, Adélie. "La Primaquine, une thérapie innovante et ciblée pour les pathologies associées à l’infection par l’Herpèsvirus humain 8". Electronic Thesis or Diss., Sorbonne université, 2021. https://accesdistant.sorbonne-universite.fr/login?url=https://theses-intra.sorbonne-universite.fr/2021SORUS148.pdf.
Texto completo da fonteThe Human Herpesvirus 8 (HHV-8) is one of seven recognized human cancer causing viruses. HHV-8 is a principal causative agent of several human cancers including Kaposi’s sarcoma (KS), multicentric Castleman’s disease (MCD) and primary effusion lymphoma (PEL), which represent important and difficult to treat clinical problem, with very few therapeutic options. In the present in vitro study, we demonstrated the specific cytotoxic and pro-apoptotic effect of the antimalarial primaquine disphosphate in HHV-8-infected PEL cells, without any toxicity on different uninfected cells. We also found that primaquine-induced oxidative stress and pro-apoptotic UPR activated by excessive reticulum endoplasmic stress, to be part of the pro-apoptotic mechanisms of action of primaquine in PEL cells. Finally, PQ treatment had a clinical positive effect on tumor growth in a in vivo NOD/SCID xenograft PEL mouse model, as well as in a pilot clinical study in human harboring very severe KS. Importantly, primaquine was well tolerated and none adverse event and overt toxic effects were observed in both primaquine-treated mice and patients. The combination of preclinical and clinical observations and results from our analysis thereby raising the possibility that primaquine may be used as a promising targeted agent in treatment of HHV-8-associated cancers
Astruc, Marie-Pierre. "Maladie de Castleman : revue de la litterature, à propos d'une observation". Montpellier 1, 1990. http://www.theses.fr/1990MON11293.
Texto completo da fonteGOUZENES, STEPHANE. "A propos d'un cas de la maladie de castleman de type plasmocytaire". Toulouse 3, 1991. http://www.theses.fr/1991TOU31093.
Texto completo da fonteBerger, Françoise. "L'hyperplasie lymphoide angio-folliculaire : syndrome(s) ou maladie(s) ; six observations recentes confrontees aux donnees de la litterature". Saint-Etienne, 1989. http://www.theses.fr/1989STET6202.
Texto completo da fonteGaspard, Catherine. "Hyperplasie angiofolliculaire ou maladie de Castelman : étude anatomo-clinique de 10 cas et revue de la littérature". Montpellier 1, 1996. http://www.theses.fr/1996MON11063.
Texto completo da fontePHILIBERT, PATRICK. "Sarcome de kaposi extensif au cours d'un deficit immunitaire acquis en dehors de toute greffe d'organe et d'infection par le virus de l'immuno-deficience humaine : a propos d'une observation de maladie de castleman". Aix-Marseille 2, 1988. http://www.theses.fr/1988AIX20408.
Texto completo da fonteNguyen-Khac, Eric. "Maladie alcoolique du foie : génétique, diagnostic, et thérapeutique". Amiens, 2008. http://www.theses.fr/2008AMIED006.
Texto completo da fonteDa, Silva Afitz. "Glycovecteurs pour le ciblage thérapeutique d'une maladie rare lysosomale : la maladie de Pompe". Thesis, Montpellier, 2017. http://www.theses.fr/2017MONTT001.
Texto completo da fonteOn 53 known rare lysosomal diseases, only 8 can be treated by enzyme replacement therapy with more or less efficiency. There is therefore a need to develop new treatments but also to better characterize these diseases. During this thesis, we focused on Pompe disease which results from the absence or deficiency of the lysosomal enzyme alpha-glucosidase acid (GAA), responsible for the degradation of glycogen in glucose in many tissues. Currently only the infantile form of this disease can be treated while the juvenile/adult form is slightly improved by Myozyme® treatment. This thesis aimed to devel a new enzyme replacement therapy which could prevent the progression of the disease and satisfactorily treat the late onset form of the disease. To do that, we used monosaccharide derivatives “Mannose-6-phosphate analogues (M6P) Functionalized on Aglycone (AMFA)”, which were grafted onto human recombinant GAA (rhGAA) in order to improve its lysosome addressing obtaining the rhGAA-AMFA.A first in vitro study on adult patient fibroblasts showed that the addition of AMFA to rhGAA, produced in Sf9 insect cells, significantly improved its affinity for the M6P receptor (RM6P), its internalization and activity. It was also more efficient on the GAA-/- Pompe mouse model compared to current treatment (Article 1). Then, we demonstrated for the first time the efficiency of rhGAA-AMFA produced in CHO cells in aged mice model. These results suggest the possibility to use this neo-enzyme in the treatment of the adult form that still resists to treatment (Article 2). Finally, the addition of AMFA allows a complete maturation of rhGAA into its active form in myoblasts and myotubes of adult patients and in the quadriceps of aged mice Pompe model. This was not observed for Myozyme® (Article 3). In this thesis we have also demonstrated that novel disaccharide analogues with a better affinity than monosaccharides for RM6P can efficiently target GAA for the treatment of Pompe disease. A patent has been filed on these results (Patent PCT / FR2016 / 052339).In conclusion, this work has led to the development of a new technology more efficient in targeting lysosomal enzymes by mean of new synthetic analogues. An orphan drug designation for the recombinant human acid alpha-glucosidase conjugated with mannose-6-phosphate analogues was obtained on the basis of this work at the European Medicines Agency for the treatment of Pompe disease (EMA/OD/098/16).Key words: lysosomal diseases, Pompe disease, enzyme replacement therapy, mannose 6-phosphate receptor
Phélizon, Claire. "La maladie d'Alzheimer ou les difficultés de l'approche thérapeutique". Bordeaux 2, 1999. http://www.theses.fr/1999BOR2P099.
Texto completo da fonteKy, Tchouan. "Maladie de Castleman à forme multicentrique avec transformation monoclonale : étude à partir d'une observation et revue de la littérature". Bordeaux 2, 1995. http://www.theses.fr/1995BOR2M048.
Texto completo da fonteLivros sobre o assunto "Maladie de Castleman – Thérapeutique"
-Ph, Assal J., ed. L' éducation thérapeutique des patients: Nouvelles approches de la maladie chronique. 2a ed. Paris: Maloine, 2003.
Encontre o texto completo da fonteActivité physique, santé et maladie. Montréal, Qué: Éditions Québec/Amérique, 1988.
Encontre o texto completo da fonteComprendre le Parkinson. Montréal: Modus vivendi, 2008.
Encontre o texto completo da fonteP, Rang H., ed. Pharmacology. 5a ed. New York: Churchill Livingstone, 2003.
Encontre o texto completo da fontePharmacology. 4a ed. New York: Churchill Livingstone, 2001.
Encontre o texto completo da fonteJacques, Roux-Brioude, Labbé Elodie, Munsch Frédéric e Munsch-Roux Kathia, eds. La méthode de Naomi Feil à l'usage des familles: La validation, pour garder le lien avec un proche âgé désorienté. 2a ed. Rueil-Malmaison: Éditions Lamarre, 2015.
Encontre o texto completo da fonteGuérir des autres. [Montréal]: Éditions de l'Homme, 1991.
Encontre o texto completo da fonteLe régime anti-inflammatoire: Comment vaincre le mal silencieux qui détruit votre santé. [Montréal]: Éditions de l'Homme, 2006.
Encontre o texto completo da fonteVotre enfant et les médicaments: Informations et conseils. Montréal: Éditions de l'Hôpital Sainte-Justine, 2005.
Encontre o texto completo da fontePrenez votre santé en main! Paris: Albin Michel, 2015.
Encontre o texto completo da fonteCapítulos de livros sobre o assunto "Maladie de Castleman – Thérapeutique"
Tessari, L. "Approche Thérapeutique de la Maladie Variqueuse à Propos de 4 Cas". In Phlebology ’95, 446–51. London: Springer London, 1995. http://dx.doi.org/10.1007/978-1-4471-3095-6_192.
Texto completo da fonteTraynard, P. Y., e R. Gagnayre. "L’éducation thérapeutique du patient atteint de maladie chronique". In Éducation thérapeutique, 3–7. Elsevier, 2009. http://dx.doi.org/10.1016/b978-2-294-70467-3.00001-4.
Texto completo da fonteSantiago-Delefosse, M. "Fonction psychologique des « théories subjectives » de la maladie". In Éducation thérapeutique, 103–8. Elsevier, 2009. http://dx.doi.org/10.1016/b978-2-294-70467-3.00013-0.
Texto completo da fonteTraynard, P. Y., e R. Gagnayre. "L’éducation thérapeutique du patient atteint de maladie chronique". In Éducation Thérapeutique, 3–8. Elsevier, 2020. http://dx.doi.org/10.1016/b978-2-294-76931-3.00001-9.
Texto completo da fontePagès, Arnaud, e Philippe Cestac. "Traitement de la maladie d'Alzheimer". In Pharmacie Clinique et Thérapeutique, 627–35. Elsevier, 2018. http://dx.doi.org/10.1016/b978-2-294-75077-9.00035-9.
Texto completo da fonteFernandez, Christine, e Christian Derouesné. "Traitement de la maladie d'Alzheimer". In Pharmacie clinique et thérapeutique, 815–24. Elsevier, 2008. http://dx.doi.org/10.1016/b978-2-294-06234-6.50039-9.
Texto completo da fonte"Contexte de la maladie chronique et prévention". In Pratiquer L'éducation Thérapeutique, 5–10. Elsevier, 2016. http://dx.doi.org/10.1016/b978-2-294-75202-5.00001-1.
Texto completo da fontela Tribonnière, X. de, e M. Albouy. "Contexte de la maladie chronique et prévention". In Pratiquer L'éducation Thérapeutique, 3–10. Elsevier, 2023. http://dx.doi.org/10.1016/b978-2-294-77885-8.00001-1.
Texto completo da fonteLacroix, A. "Autour du vécu psychique des patients atteints d'une maladie chronique". In Éducation thérapeutique, 33–38. Elsevier, 2009. http://dx.doi.org/10.1016/b978-2-294-70467-3.00005-1.
Texto completo da fonteLacroix, A. "Autour du vécu psychique des patients atteints d’une maladie chronique". In Éducation Thérapeutique, 75–81. Elsevier, 2020. http://dx.doi.org/10.1016/b978-2-294-76931-3.00009-3.
Texto completo da fonteTrabalhos de conferências sobre o assunto "Maladie de Castleman – Thérapeutique"
Fricain, J. C. "Mucites : une prise en charge basée sur la preuve". In 66ème Congrès de la SFCO. Les Ulis, France: EDP Sciences, 2020. http://dx.doi.org/10.1051/sfco/20206601008.
Texto completo da fonteLafont, J., J. H. Catherine, M. Lejeune, U. Ordioni, R. Lan e F. Campana. "Manifestations buccales de la sclérose tubéreuse de Bourneville". In 66ème Congrès de la SFCO. Les Ulis, France: EDP Sciences, 2020. http://dx.doi.org/10.1051/sfco/20206603014.
Texto completo da fonteCeddaha Zibi, A. "Migraine faciale à expression dentaire, à propos de trois cas". In 66ème Congrès de la SFCO. Les Ulis, France: EDP Sciences, 2020. http://dx.doi.org/10.1051/sfco/20206603016.
Texto completo da fonteOujdad, S., S. Zafad, H. El Attar e I. Ben Yahya. "Histiocytose langerhansienne de l’adulte : à propos d’un cas". In 66ème Congrès de la SFCO. Les Ulis, France: EDP Sciences, 2020. http://dx.doi.org/10.1051/sfco/20206603013.
Texto completo da fonteAkerzoul, N., e S. Chbicheb. "Cartographie des cancers de la cavité orale chez l’enfant". In 66ème Congrès de la SFCO. Les Ulis, France: EDP Sciences, 2020. http://dx.doi.org/10.1051/sfco/20206603005.
Texto completo da fonte